^
Association details:
| Biomarker: | KDR overexpression |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Sutent (sunitinib) (c-KIT inhibitor, VEGFR inhibitor, PDGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Refractory Angiosarcoma of the Breast with VEGFR 2 Upregulation Successfully Treated with Sunitinib
Excerpt:
The Caris gene expression assay performed earlier demonstrated a potential therapeutic benefit of sunitinib due to the upregulation of VEGFR2. Sunitinib was then started at 50 mg daily and within 2 months the patient had a complete resolution of all her tumors (Fig. 1B). Fifteen months after the enactment of sunitinib, the patient is disease free, on a maintenance dose of 25 mg daily of sunitinib.
DOI:
10.1111/tbj.12380
